Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms

Chen Hsun Ho, Ting Chen Chang, Ho Hsiung Lin, Shih Ping Liu, Kuo How Huang, Hong Jeng Yu

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background/Purpose: Various antimuscarinic agents have been developed for the treatment of overactive bladder (OAB). More data comparing these agents are still required. This study evaluated the efficacy and safety of solifenacin and tolterodine in Taiwanese patients with OAB symptoms. Methods: This was a prospective, randomized, open-label study. A total of 75 patients (25 men and 50 women) with OAB symptoms were randomized to treatment with solifenacin (n = 39) or tolterodine (n = 36). Efficacy and safety variables were assessed and compared with the baseline and between the two groups. Results: At week 12, solifenacin and tolterodine demonstrated equal efficacy in reducing the number of micturition (-2.56 ±3.31 vs. -2.44 ± 4.56, p = 0.58), urgency (-1.70 ± 3.07 vs. -1.15 ± 2.68, p =0.37) and incontinence (-2.79 ± 2.82 vs. -4.67 ± 9.29, p =0.28) episodes per 24 hours. There was no difference in improvement of the quality of life. The patient and physician assessments of treatment benefit were not statistically different for solifenacin and tolterodine (p = 0.23 and p = 0.52, respectively), with the majority showing benefits in both groups. The incidence of major adverse events, including dry mouth (18.0% vs. 8.3%, p = 0.31) and constipation (12.8% vs. 2.8%, p = 0.20) was not significantly different. Compared with baseline, the severity of dry mouth did not increase in either group. Conclusion: Both solifenacin and tolterodine are effective in treating key OAB symptoms, including urinary frequency, urgency and incontinence in the Taiwanese population. Both medications are comparably effective and safe, with the most common adverse effects being dry mouth and constipation.

Original languageEnglish
Pages (from-to)702-708
Number of pages7
JournalJournal of the Formosan Medical Association
Volume109
Issue number10
DOIs
Publication statusPublished - Oct 1 2010
Externally publishedYes

Fingerprint

Overactive Urinary Bladder
Mouth
Constipation
Therapeutics
Safety
Muscarinic Antagonists
Urination
Quality of Life
Solifenacin Succinate
Tolterodine Tartrate
Physicians
Incidence
Population

Keywords

  • Antimuscarinic agents
  • Overactive bladder
  • Solifenacin
  • Tolterodine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms. / Ho, Chen Hsun; Chang, Ting Chen; Lin, Ho Hsiung; Liu, Shih Ping; Huang, Kuo How; Yu, Hong Jeng.

In: Journal of the Formosan Medical Association, Vol. 109, No. 10, 01.10.2010, p. 702-708.

Research output: Contribution to journalArticle

Ho, Chen Hsun ; Chang, Ting Chen ; Lin, Ho Hsiung ; Liu, Shih Ping ; Huang, Kuo How ; Yu, Hong Jeng. / Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms. In: Journal of the Formosan Medical Association. 2010 ; Vol. 109, No. 10. pp. 702-708.
@article{d414a96945ce48728d0d3d8eb0202975,
title = "Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms",
abstract = "Background/Purpose: Various antimuscarinic agents have been developed for the treatment of overactive bladder (OAB). More data comparing these agents are still required. This study evaluated the efficacy and safety of solifenacin and tolterodine in Taiwanese patients with OAB symptoms. Methods: This was a prospective, randomized, open-label study. A total of 75 patients (25 men and 50 women) with OAB symptoms were randomized to treatment with solifenacin (n = 39) or tolterodine (n = 36). Efficacy and safety variables were assessed and compared with the baseline and between the two groups. Results: At week 12, solifenacin and tolterodine demonstrated equal efficacy in reducing the number of micturition (-2.56 ±3.31 vs. -2.44 ± 4.56, p = 0.58), urgency (-1.70 ± 3.07 vs. -1.15 ± 2.68, p =0.37) and incontinence (-2.79 ± 2.82 vs. -4.67 ± 9.29, p =0.28) episodes per 24 hours. There was no difference in improvement of the quality of life. The patient and physician assessments of treatment benefit were not statistically different for solifenacin and tolterodine (p = 0.23 and p = 0.52, respectively), with the majority showing benefits in both groups. The incidence of major adverse events, including dry mouth (18.0{\%} vs. 8.3{\%}, p = 0.31) and constipation (12.8{\%} vs. 2.8{\%}, p = 0.20) was not significantly different. Compared with baseline, the severity of dry mouth did not increase in either group. Conclusion: Both solifenacin and tolterodine are effective in treating key OAB symptoms, including urinary frequency, urgency and incontinence in the Taiwanese population. Both medications are comparably effective and safe, with the most common adverse effects being dry mouth and constipation.",
keywords = "Antimuscarinic agents, Overactive bladder, Solifenacin, Tolterodine",
author = "Ho, {Chen Hsun} and Chang, {Ting Chen} and Lin, {Ho Hsiung} and Liu, {Shih Ping} and Huang, {Kuo How} and Yu, {Hong Jeng}",
year = "2010",
month = "10",
day = "1",
doi = "10.1016/S0929-6646(10)60114-3",
language = "English",
volume = "109",
pages = "702--708",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms

AU - Ho, Chen Hsun

AU - Chang, Ting Chen

AU - Lin, Ho Hsiung

AU - Liu, Shih Ping

AU - Huang, Kuo How

AU - Yu, Hong Jeng

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Background/Purpose: Various antimuscarinic agents have been developed for the treatment of overactive bladder (OAB). More data comparing these agents are still required. This study evaluated the efficacy and safety of solifenacin and tolterodine in Taiwanese patients with OAB symptoms. Methods: This was a prospective, randomized, open-label study. A total of 75 patients (25 men and 50 women) with OAB symptoms were randomized to treatment with solifenacin (n = 39) or tolterodine (n = 36). Efficacy and safety variables were assessed and compared with the baseline and between the two groups. Results: At week 12, solifenacin and tolterodine demonstrated equal efficacy in reducing the number of micturition (-2.56 ±3.31 vs. -2.44 ± 4.56, p = 0.58), urgency (-1.70 ± 3.07 vs. -1.15 ± 2.68, p =0.37) and incontinence (-2.79 ± 2.82 vs. -4.67 ± 9.29, p =0.28) episodes per 24 hours. There was no difference in improvement of the quality of life. The patient and physician assessments of treatment benefit were not statistically different for solifenacin and tolterodine (p = 0.23 and p = 0.52, respectively), with the majority showing benefits in both groups. The incidence of major adverse events, including dry mouth (18.0% vs. 8.3%, p = 0.31) and constipation (12.8% vs. 2.8%, p = 0.20) was not significantly different. Compared with baseline, the severity of dry mouth did not increase in either group. Conclusion: Both solifenacin and tolterodine are effective in treating key OAB symptoms, including urinary frequency, urgency and incontinence in the Taiwanese population. Both medications are comparably effective and safe, with the most common adverse effects being dry mouth and constipation.

AB - Background/Purpose: Various antimuscarinic agents have been developed for the treatment of overactive bladder (OAB). More data comparing these agents are still required. This study evaluated the efficacy and safety of solifenacin and tolterodine in Taiwanese patients with OAB symptoms. Methods: This was a prospective, randomized, open-label study. A total of 75 patients (25 men and 50 women) with OAB symptoms were randomized to treatment with solifenacin (n = 39) or tolterodine (n = 36). Efficacy and safety variables were assessed and compared with the baseline and between the two groups. Results: At week 12, solifenacin and tolterodine demonstrated equal efficacy in reducing the number of micturition (-2.56 ±3.31 vs. -2.44 ± 4.56, p = 0.58), urgency (-1.70 ± 3.07 vs. -1.15 ± 2.68, p =0.37) and incontinence (-2.79 ± 2.82 vs. -4.67 ± 9.29, p =0.28) episodes per 24 hours. There was no difference in improvement of the quality of life. The patient and physician assessments of treatment benefit were not statistically different for solifenacin and tolterodine (p = 0.23 and p = 0.52, respectively), with the majority showing benefits in both groups. The incidence of major adverse events, including dry mouth (18.0% vs. 8.3%, p = 0.31) and constipation (12.8% vs. 2.8%, p = 0.20) was not significantly different. Compared with baseline, the severity of dry mouth did not increase in either group. Conclusion: Both solifenacin and tolterodine are effective in treating key OAB symptoms, including urinary frequency, urgency and incontinence in the Taiwanese population. Both medications are comparably effective and safe, with the most common adverse effects being dry mouth and constipation.

KW - Antimuscarinic agents

KW - Overactive bladder

KW - Solifenacin

KW - Tolterodine

UR - http://www.scopus.com/inward/record.url?scp=77958115871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958115871&partnerID=8YFLogxK

U2 - 10.1016/S0929-6646(10)60114-3

DO - 10.1016/S0929-6646(10)60114-3

M3 - Article

C2 - 20970066

AN - SCOPUS:77958115871

VL - 109

SP - 702

EP - 708

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

IS - 10

ER -